Chronic Prostatitis With Chronic Pelvic Pain Syndrome
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
OM PharmaOM-89 [Uro-Vaxom® Capsule]
AbbVieBotulinum Toxin Type A
Clinical Trials (2)
Total enrollment: 343 patients across 2 trials
The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Start: Dec 2023Est. completion: Mar 2026332 patients
Phase 4Recruiting
Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome
Start: Apr 2007Est. completion: Jun 201311 patients
Phase 3Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 343 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.